BeOne Medicines (BEIGF) EBITDA Margin Growth (5y) (2020 - 2026)
Powered by 
Analysis
BeOne Medicines (BEIGF) EBITDA Margin Growth (5y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.47 Bn | 624.71 Bn | 17.26 Bn |
| 2 | AbbVie | 439.99 Bn | 433.42 Bn | 12.70 Bn |
| 3 | Merck | 365.45 Bn | 358.31 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33,564.00 |
| Mar 31, 2026 | 493.00 |
| Dec 31, 2025 | 49,678.00 |
| Sep 30, 2025 | 49,479.00 |
| Jun 30, 2025 | 55,346.00 |
| Mar 31, 2025 | 71,894.00 |
| Dec 31, 2024 | 67,502.00 |
| Sep 30, 2024 | 61,077.00 |
| Jun 30, 2024 | 2,374.00 |
| Mar 31, 2024 | 18,847.00 |
| Dec 31, 2023 | 41,813.00 |
| Sep 30, 2023 | 26,163.00 |
| Jun 30, 2023 | 25,524.00 |
| Mar 31, 2023 | 25,758.00 |
| Dec 31, 2022 | 44,784.00 |
| Sep 30, 2022 | -16,527.00 |
| Jun 30, 2021 | 595,009.00 |
| Mar 31, 2021 | 301,513.00 |
| Dec 31, 2020 | 7,952.00 |
| Sep 30, 2020 | 53,067.00 |